A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.